These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11750171)

  • 1. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
    Jones RN; Beach ML; Pfaller MA
    Diagn Microbiol Infect Dis; 2001 Nov; 41(3):161-3. PubMed ID: 11750171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).
    Gales AC; Jones RN; Gordon KA; Sader HS; Wilke WW; Beach ML; Pfaller MA; Doern GV
    J Antimicrob Chemother; 2000 Mar; 45(3):295-303. PubMed ID: 10702547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
    Kirby JT; Mutnick AH; Jones RN; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):303-9. PubMed ID: 12151191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000).
    Gordon KA; Jones RN;
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):295-301. PubMed ID: 12730002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. The SENTRY Antimicrobial Surveillance Group (Americas and Europe).
    Odland BA; Jones RN; Verhoef J; Fluit A; Beach ML
    Diagn Microbiol Infect Dis; 1999 Aug; 34(4):315-20. PubMed ID: 10459483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
    Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
    Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
    Fedler KA; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):427-36. PubMed ID: 16938419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
    Jones RN; Beach ML; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):247-52. PubMed ID: 9884844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001).
    Sader HS; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2003 Sep; 47(1):361-4. PubMed ID: 12967751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
    Fedler KA; Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):157-64. PubMed ID: 16529904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
    Hansen GT; Blondeau JM
    J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.
    Karlowsky JA; Kelly LJ; Thornsberry C; Jones ME; Evangelista AT; Critchley IA; Sahm DF
    Int J Antimicrob Agents; 2002 Jan; 19(1):21-31. PubMed ID: 11814764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000).
    Gales AC; Sader HS; Jones RN;
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):289-99. PubMed ID: 12493177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.